7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most children with biallelic SMN1 deletions and three SMN2 copies develop spinal muscular atrophy (SMA) type 2. SPR1NT ( NCT03505099), a Phase III, multicenter, single-arm trial, investigated the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated within six postnatal weeks. Of 15 children with three SMN2 copies treated before symptom onset, all stood independently before 24 months ( P < 0.0001; 14 within normal developmental window), and 14 walked independently ( P < 0.0001; 11 within normal developmental window). All survived without permanent ventilation at 14 months; ten (67%) maintained body weight (≥3rd WHO percentile) without feeding support through 24 months; and none required nutritional or respiratory support. No serious adverse events were considered treatment-related by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.

          Abstract

          For infants with three copies of SMN1 at risk for spinal muscular atrophy (SMA) type 1, onasemnogene abeparvovec improves ventilator-free survival and nutritional/respiratory independence and allows motor development indistinguishable from healthy children without SMA.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Initial sequencing and analysis of the human genome.

          The human genome holds an extraordinary trove of information about human development, physiology, medicine and evolution. Here we report the results of an international collaboration to produce and make freely available a draft sequence of the human genome. We also present an initial analysis of the data, describing some of the insights that can be gleaned from the sequence.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

            Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Initial impact of the sequencing of the human genome.

              The sequence of the human genome has dramatically accelerated biomedical research. Here I explore its impact, in the decade since its publication, on our understanding of the biological functions encoded in the genome, on the biological basis of inherited diseases and cancer, and on the evolution and history of the human species. I also discuss the road ahead in fulfilling the promise of genomics for medicine.
                Bookmark

                Author and article information

                Contributors
                kstrauss@clinicforspecialchildren.org
                Journal
                Nat Med
                Nat Med
                Nature Medicine
                Nature Publishing Group US (New York )
                1078-8956
                1546-170X
                17 June 2022
                17 June 2022
                : 1-8
                Affiliations
                [1 ]GRID grid.418640.f, Clinic for Special Children, ; Strasburg, PA USA
                [2 ]GRID grid.415783.c, ISNI 0000 0004 0418 2120, Penn Medicine-Lancaster General Hospital, ; Lancaster, PA USA
                [3 ]GRID grid.168645.8, ISNI 0000 0001 0742 0364, Departments of Pediatrics and Molecular, Cell & Cancer Biology, , University of Massachusetts School of Medicine, ; Worcester, MA USA
                [4 ]GRID grid.430417.5, ISNI 0000 0004 0640 6474, Department of Neurology, , Sydney Children’s Hospital Network, ; Sydney, NSW Australia
                [5 ]GRID grid.1005.4, ISNI 0000 0004 4902 0432, School of Clinical Medicine, , UNSW Medicine and Health, UNSW Sydney, ; Sydney, NSW Australia
                [6 ]GRID grid.83440.3b, ISNI 0000000121901201, The Dubowitz Neuromuscular Centre, , University College London, Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, ; London, UK
                [7 ]GRID grid.420468.c, National Institute of Health Research, , Great Ormond Street Hospital Biomedical Research Centre, ; London, UK
                [8 ]GRID grid.410818.4, ISNI 0000 0001 0720 6587, Institute of Medical Genetics, , Tokyo Women’s Medical University, ; Tokyo, Japan
                [9 ]GRID grid.240344.5, ISNI 0000 0004 0392 3476, Center for Gene Therapy, , Nationwide Children’s Hospital, ; Columbus, OH USA
                [10 ]GRID grid.261331.4, ISNI 0000 0001 2285 7943, Department of Pediatrics and Department of Neurology, , The Ohio State University, ; Columbus, OH USA
                [11 ]Department of Paediatrics, MDUK Oxford Neuromuscular Centre, Oxford, UK
                [12 ]GRID grid.4861.b, ISNI 0000 0001 0805 7253, Neuromuscular Reference Center, Department of Pediatrics, , CHU & University of Liège, ; Liège, Belgium
                [13 ]GRID grid.14709.3b, ISNI 0000 0004 1936 8649, Department of Pediatrics, Neurology & Neurosurgery, Montreal Children’s Hospital, , McGill University, ; Montreal, QC Canada
                [14 ]GRID grid.428618.1, ISNI 0000 0004 0456 3687, Department of Pediatrics, , Nemours Children’s Hospital, ; Orlando, FL USA
                [15 ]GRID grid.240871.8, ISNI 0000 0001 0224 711X, Center for Experimental Neurotherapeutics, St. Jude Children’s Research Hospital, ; Memphis, TN USA
                [16 ]GRID grid.32224.35, ISNI 0000 0004 0386 9924, Department of Neurology, , Massachusetts General Hospital, ; Boston, MA USA
                [17 ]GRID grid.14003.36, ISNI 0000 0001 2167 3675, Department of Neurology, , University of Wisconsin School of Medicine and Public Health, ; Madison, WI USA
                [18 ]GRID grid.4367.6, ISNI 0000 0001 2355 7002, Washington University School of Medicine, ; St. Louis, MO USA
                [19 ]GRID grid.239585.0, ISNI 0000 0001 2285 2675, Division of Pediatric Neurology, , Columbia University Medical Center, ; New York, NY USA
                [20 ]GRID grid.267313.2, ISNI 0000 0000 9482 7121, Department of Pediatrics, , University of Texas Southwestern Medical Center, ; Dallas, TX USA
                [21 ]GRID grid.413656.3, ISNI 0000 0004 0450 6121, Department of Neurology, , Helen DeVos Children’s Hospital, ; Grand Rapids, MI USA
                [22 ]GRID grid.430503.1, ISNI 0000 0001 0703 675X, Department of Pediatrics, , University of Colorado School of Medicine, ; Aurora, CO USA
                [23 ]GRID grid.19006.3e, ISNI 0000 0000 9632 6718, Department of Neurology, , David Geffen School of Medicine at UCLA, ; Los Angeles, CA USA
                [24 ]Novartis Gene Therapies, Inc., Bannockburn, IL USA
                [25 ]GRID grid.418424.f, ISNI 0000 0004 0439 2056, Translational Medicine, Novartis Institutes for BioMedical Research, ; Cambridge, MA USA
                Author information
                http://orcid.org/0000-0002-6429-8657
                http://orcid.org/0000-0002-4472-0902
                http://orcid.org/0000-0003-2632-0873
                http://orcid.org/0000-0001-9270-4061
                http://orcid.org/0000-0001-8927-2018
                http://orcid.org/0000-0002-9351-7054
                http://orcid.org/0000-0002-4593-6342
                http://orcid.org/0000-0003-0851-3516
                http://orcid.org/0000-0002-3552-7369
                http://orcid.org/0000-0001-7688-1818
                Article
                1867
                10.1038/s41591-022-01867-3
                9205287
                35715567
                81110e0e-80cb-45f2-a546-08ab321c4365
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 February 2022
                : 10 May 2022
                Funding
                Funded by: Novartis Gene Therapies, Inc., sponsored this study.
                Categories
                Article

                Medicine
                gene therapy,development
                Medicine
                gene therapy, development

                Comments

                Comment on this article